Re: Fwd: Celiac disease vaccine shows promising results in Phase I trial

[Guest guest]

I cannot even stand to read the article! Its nuts! It only would seem that it

will make matters worse introducing more inflammation. I pity anyone person that

gets goated into taking the vaccine thinking their life will improve.

Allie

>

> Anyone else think this sounds like a crazy idea?

>

> Nora

>

> >

> > http://www.sciencedaily.com/releases/2011/05/110509091559.htm

> > Celiac Disease Vaccine Shows Promising Results in Phase I Trial

> >

> > ScienceDaily (May 8, 2011) — The world's first potential vaccine for celiac

disease has shown promising results for treating celiac disease in a Phase I

clinical trial and is expected to move to Phase II trials within the next year.

> >

> > The Phase I trial undertaken in Melbourne, Australia, evaluated the safety,

tolerability and bioactivity of the vaccine Nexvax2®, which has been developed

for celiac disease. Celiac disease is an autoimmune disease caused by an immune

reaction to the gluten protein found in wheat, rye and barley.

> > The three peptides on which the vaccine is based were identified by Dr Bob

from the Walter and Eliza Hall Institute's Immunology division. The

vaccine is being further developed by US biotechnology company ImmusanT, of

which Dr is Chief Scientific and Medical Officer. Dr presented

the Phase I trial results May 8 at the Digestive Disease Week symposium in

Chicago, Illinois, US.

> >

> > " Nexvax2® aims to desensitise patients to the three specific peptides in

gluten that we have previously identified as 'toxic' to people with celiac

disease, " Dr said. " Our Phase I study showed that Nexvax2® was safe to

use and well tolerated, and importantly, that it had the desired biological

response in patients with celiac disease. "

> >

> > Up to one per cent of the global population is affected by celiac disease,

which is currently only treatable by eliminating gluten from the diet. In people

with celiac disease, immune cells react to gluten and trigger an immune response

that damages the lining of the small intestine and inhibits its ability to

absorb nutrients from food.

> >

> > Dr said the vaccine would be suitable for treating the

approximately 90 per cent of celiac disease patients with the DQ2 genetic form

of disease.

> >

> > " In our Phase I trial, we saw a Nexvax2®-specific T-cell response that

confirms the desired bioactivity in HLA-DQ2 genotype patients, " Dr

said. " We expect the vaccine to enter Phase II trials within the next 10 months,

and hope to demonstrate a dramatic reduction in the body's rejection of dietary

gluten so patients can resume a normal diet and return to good health. "

> >

> > The Phase I study evaluated the effect of weekly injections of Nexvax2® over

three weeks in celiac patients on a strict gluten-free diet. At the highest

doses, some patients had gastrointestinal symptoms similar to what they'd

experience after eating gluten products. This suggests the vaccine uses the

correct peptides for eventually being able to tolerate gluten.

> >

> > Dr said the peptides used as part of the vaccine could also be used

to improve diagnostic testing of celiac disease.

> >

> > " Diagnosing celiac disease can be quite costly, requiring invasive tests and

biopsies to confirm the disease, " Dr said. " The results of a population

study suggest that a combination of blood and genetic testing could effectively

diagnose celiac disease without these painful and invasive tests, with up to 50

per cent reduction in costs as well, which creates a win-win situation. "

> >

> > ImmusanT is collaborating with INOVA Diagnostics to develop improved

serologic tests for celiac disease. In addition, ImmusanT is developing a

functional T-cell diagnostic, designed to be used both as a standalone test as

well as a monitoring test for Nexvax2.

> >

> > Follow ImmusanT's progress at: www.immusanT.com.

> >

>

[Guest guest]

Think it is utterly stupid, wouldnt touch it with a ten foot pole. TametAnyone else think this sounds like a crazy idea?Norahttp://www.sciencedaily.com/releases/2011/05/110509091559.htmCeliac Disease Vaccine Shows Promising Results in Phase I TrialScienceDaily (May 8, 2011) — The world's first potential vaccine for celiac disease has shown promising results for treating celiac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.The Phase I trial undertaken in Melbourne, Australia, evaluated the safety, tolerability and bioactivity of the vaccine Nexvax2®, which has been developed for celiac disease. Celiac disease is an autoimmune disease caused by an immune reaction to the gluten protein found in wheat, rye and barley.The three peptides on which the vaccine is based were identified by Dr Bob from the Walter and Eliza Hall Institute's Immunology division. The vaccine is being further developed by US biotechnology company ImmusanT, of which Dr is Chief Scientific and Medical Officer. Dr presented the Phase I trial results May 8 at the Digestive Disease Week symposium in Chicago, Illinois, US."Nexvax2® aims to desensitise patients to the three specific peptides in gluten that we have previously identified as 'toxic' to people with celiac disease," Dr said. "Our Phase I study showed that Nexvax2® was safe to use and well tolerated, and importantly, that it had the desired biological response in patients with celiac disease."Up to one per cent of the global population is affected by celiac disease, which is currently only treatable by eliminating gluten from the diet. In people with celiac disease, immune cells react to gluten and trigger an immune response that damages the lining of the small intestine and inhibits its ability to absorb nutrients from food.Dr said the vaccine would be suitable for treating the approximately 90 per cent of celiac disease patients with the DQ2 genetic form of disease."In our Phase I trial, we saw a Nexvax2®-specific T-cell response that confirms the desired bioactivity in HLA-DQ2 genotype patients," Dr said. "We expect the vaccine to enter Phase II trials within the next 10 months, and hope to demonstrate a dramatic reduction in the body's rejection of dietary gluten so patients can resume a normal diet and return to good health."The Phase I study evaluated the effect of weekly injections of Nexvax2® over three weeks in celiac patients on a strict gluten-free diet. At the highest doses, some patients had gastrointestinal symptoms similar to what they'd experience after eating gluten products. This suggests the vaccine uses the correct peptides for eventually being able to tolerate gluten.Dr said the peptides used as part of the vaccine could also be used to improve diagnostic testing of celiac disease."Diagnosing celiac disease can be quite costly, requiring invasive tests and biopsies to confirm the disease," Dr said. "The results of a population study suggest that a combination of blood and genetic testing could effectively diagnose celiac disease without these painful and invasive tests, with up to 50 per cent reduction in costs as well, which creates a win-win situation."ImmusanT is collaborating with INOVA Diagnostics to develop improved serologic tests for celiac disease. In addition, ImmusanT is developing a functional T-cell diagnostic, designed to be used both as a standalone test as well as a monitoring test for Nexvax2.Follow ImmusanT's progress at: www.immusanT.com.

[Guest guest]

This is the first time I've heard of treating an AUTOimmune disease with an

approach that triggers immune response. Doesn't make sense to me.

Jo

> >

> > Anyone else think this sounds like a crazy idea?

> >

> > Nora

> >

> > >

> > > http://www.sciencedaily.com/releases/2011/05/110509091559.htm

> > > Celiac Disease Vaccine Shows Promising Results in Phase I Trial

> > >

> > > ScienceDaily (May 8, 2011) — The world's first potential vaccine for

celiac disease has shown promising results for treating celiac disease in a

Phase I clinical trial and is expected to move to Phase II trials within the

next year.

> > >

> > > The Phase I trial undertaken in Melbourne, Australia, evaluated the

safety, tolerability and bioactivity of the vaccine Nexvax2®, which has been

developed for celiac disease. Celiac disease is an autoimmune disease caused by

an immune reaction to the gluten protein found in wheat, rye and barley.

> > > The three peptides on which the vaccine is based were identified by Dr Bob

from the Walter and Eliza Hall Institute's Immunology division. The

vaccine is being further developed by US biotechnology company ImmusanT, of

which Dr is Chief Scientific and Medical Officer. Dr presented

the Phase I trial results May 8 at the Digestive Disease Week symposium in

Chicago, Illinois, US.

> > >

> > > " Nexvax2® aims to desensitise patients to the three specific peptides in

gluten that we have previously identified as 'toxic' to people with celiac

disease, " Dr said. " Our Phase I study showed that Nexvax2® was safe to

use and well tolerated, and importantly, that it had the desired biological

response in patients with celiac disease. "

> > >

> > > Up to one per cent of the global population is affected by celiac disease,

which is currently only treatable by eliminating gluten from the diet. In people

with celiac disease, immune cells react to gluten and trigger an immune response

that damages the lining of the small intestine and inhibits its ability to

absorb nutrients from food.

> > >

> > > Dr said the vaccine would be suitable for treating the

approximately 90 per cent of celiac disease patients with the DQ2 genetic form

of disease.

> > >

> > > " In our Phase I trial, we saw a Nexvax2®-specific T-cell response that

confirms the desired bioactivity in HLA-DQ2 genotype patients, " Dr

said. " We expect the vaccine to enter Phase II trials within the next 10 months,

and hope to demonstrate a dramatic reduction in the body's rejection of dietary

gluten so patients can resume a normal diet and return to good health. "

> > >

> > > The Phase I study evaluated the effect of weekly injections of Nexvax2®

over three weeks in celiac patients on a strict gluten-free diet. At the highest

doses, some patients had gastrointestinal symptoms similar to what they'd

experience after eating gluten products. This suggests the vaccine uses the

correct peptides for eventually being able to tolerate gluten.

> > >

> > > Dr said the peptides used as part of the vaccine could also be

used to improve diagnostic testing of celiac disease.

> > >

> > > " Diagnosing celiac disease can be quite costly, requiring invasive tests

and biopsies to confirm the disease, " Dr said. " The results of a

population study suggest that a combination of blood and genetic testing could

effectively diagnose celiac disease without these painful and invasive tests,

with up to 50 per cent reduction in costs as well, which creates a win-win

situation. "

> > >

> > > ImmusanT is collaborating with INOVA Diagnostics to develop improved

serologic tests for celiac disease. In addition, ImmusanT is developing a

functional T-cell diagnostic, designed to be used both as a standalone test as

well as a monitoring test for Nexvax2.

> > >

> > > Follow ImmusanT's progress at: www.immusanT.com.

> > >

> >

>

[Guest guest]

follow the money, sighTo: BorreliaMultipleInfectionsAndAutism Sent: Thu, May 12, 2011 9:41:41 PMSubject: Re: Fwd: Celiac disease vaccine shows promising results in Phase I trial

This is the first time I've heard of treating an AUTOimmune disease with an approach that triggers immune response. Doesn't make sense to me.

Jo

> >

> > Anyone else think this sounds like a crazy idea?

> >

> > Nora

> >

> > >

> > > http://www.sciencedaily.com/releases/2011/05/110509091559.htm

> > > Celiac Disease Vaccine Shows Promising Results in Phase I Trial

> > >

> > > ScienceDaily (May 8, 2011) — The world's first potential vaccine for celiac disease has shown promising results for treating celiac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

> > >

> > > The Phase I trial undertaken in Melbourne, Australia, evaluated the safety, tolerability and bioactivity of the vaccine Nexvax2®, which has been developed for celiac disease. Celiac disease is an autoimmune disease caused by an immune reaction to the gluten protein found in wheat, rye and barley.

> > > The three peptides on which the vaccine is based were identified by Dr Bob from the Walter and Eliza Hall Institute's Immunology division. The vaccine is being further developed by US biotechnology company ImmusanT, of which Dr is Chief Scientific and Medical Officer. Dr presented the Phase I trial results May 8 at the Digestive Disease Week symposium in Chicago, Illinois, US.

> > >

> > > "Nexvax2® aims to desensitise patients to the three specific peptides in gluten that we have previously identified as 'toxic' to people with celiac disease," Dr said. "Our Phase I study showed that Nexvax2® was safe to use and well tolerated, and importantly, that it had the desired biological response in patients with celiac disease."

> > >

> > > Up to one per cent of the global population is affected by celiac disease, which is currently only treatable by eliminating gluten from the diet. In people with celiac disease, immune cells react to gluten and trigger an immune response that damages the lining of the small intestine and inhibits its ability to absorb nutrients from food.

> > >

> > > Dr said the vaccine would be suitable for treating the approximately 90 per cent of celiac disease patients with the DQ2 genetic form of disease.

> > >

> > > "In our Phase I trial, we saw a Nexvax2®-specific T-cell response that confirms the desired bioactivity in HLA-DQ2 genotype patients," Dr said. "We expect the vaccine to enter Phase II trials within the next 10 months, and hope to demonstrate a dramatic reduction in the body's rejection of dietary gluten so patients can resume a normal diet and return to good health."

> > >

> > > The Phase I study evaluated the effect of weekly injections of Nexvax2® over three weeks in celiac patients on a strict gluten-free diet. At the highest doses, some patients had gastrointestinal symptoms similar to what they'd experience after eating gluten products. This suggests the vaccine uses the correct peptides for eventually being able to tolerate gluten.

> > >

> > > Dr said the peptides used as part of the vaccine could also be used to improve diagnostic testing of celiac disease.

> > >

> > > "Diagnosing celiac disease can be quite costly, requiring invasive tests and biopsies to confirm the disease," Dr said. "The results of a population study suggest that a combination of blood and genetic testing could effectively diagnose celiac disease without these painful and invasive tests, with up to 50 per cent reduction in costs as well, which creates a win-win situation."

> > >

> > > ImmusanT is collaborating with INOVA Diagnostics to develop improved serologic tests for celiac disease. In addition, ImmusanT is developing a functional T-cell diagnostic, designed to be used both as a standalone test as well as a monitoring test for Nexvax2.

> > >

> > > Follow ImmusanT's progress at: www.immusanT.com.

> > >

> >

>